# An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

> **NCT02324491** · PHASE2 · TERMINATED · sponsor: **Zafgen, Inc.** · enrollment: 152 (actual)

## Conditions studied

- Obesity
- Type 2 Diabetes

## Interventions

- **DRUG:** ZGN-440 for Injectable Suspension
- **DRUG:** ZGN-440 Placebo for Injectable Suspension

## Key facts

- **NCT ID:** NCT02324491
- **Lead sponsor:** Zafgen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** Sponsor decision to analyze available safety and efficacy data
- **Last updated:** 2016-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324491, "An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02324491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*